We first blogged about the first in-human safety study aimed at restoring hearing last January. It was one of our most read blog posts of the year. With that level of interest, we wanted to share the most recent news on this study.

The loss of inner ear hair cells is the most common cause of sensorineural hearing loss. Once damaged (due to loud noises, trauma, aging and other factors), these hair cells cannot grow back, which causes permanent hearing loss. U.S.-based biotech company Frequency Therapeutics is trying to change that. Last month, the company successfully completed the first-in-human study of FX-322, a Progenitor Cell Activation (PCA™) regenerative medicine aimed at creating new inner ear hair cells in the cochlea.